Home › Compare › MYTAY vs ABBV
MYTAY yields 24.15% · ABBV yields 3.06%● Live data
📍 MYTAY pulled ahead of the other in Year 1
Combined, MYTAY + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of MYTAY + ABBV for your $10,000?
Magyar Telekom Távközlési Nyilvánosan Müködö Részvénytársaság provides fixed-line and mobile telecommunication services for residential and small business customers in Hungary, Bulgaria, Romania, and the Republic of North Macedonia. The company operates in MT-Hungary and North Macedonia segments. It offers TV distribution, information communication, and system integration services; mobile telecommunication services, such as prepaid and postpaid plans, data plans, TV, broadband, SMS, and phone services; internet and voice, Office 365, server and data park, and machine to machine services; and sells telecommunications network and equipment. The company also provides mobile services comprising mobile tariff plans and mobilnet; IT services, including modern office, business support and security, communication solutions, IT devices, servers, and data pack services; and IoT services and data transmission solutions. In addition, it offers fixed line wholesale services comprising access, IP and data, voice, and TV services; mobile wholesale services, such as mobile interconnect and interworking products, and roaming services; international wholesale voice and data services, as well as IPv6 dual-stack services to its residential customers. Further, the company provides system integration and IT services, as well as operates as an interactive service provider of telecommunications applications and telebikes community. It offers its services under the Telekom and T-Systems brands. The company was incorporated in 1991 and is headquartered in Budapest, Hungary. Magyar Telekom Távközlési Nyilvánosan Müködö Részvénytársaság is a subsidiary of Deutsche Telekom Europe B.V.
Full MYTAY Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.